UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Stem Cell Transplantation
  • Publication Type:
    Chapter
  • Authors:
    Craddock C, Chakraverty R
  • Publication date:
    06/11/2015
  • Pagination:
    651, 675
  • ISBN-13:
    9781118854327
  • Status:
    Published
  • Book title:
    Postgraduate Haematology: Seventh Edition
Abstract
Haemopoietic stem cell transplantation (SCT) represents an important and increasingly utilized curative therapy in haematological malignancies and has an emerging role in the management of patients with haemoglobinopathies and bone marrow failure. (Figure 1) Autologous transplantation remains an important treatment strategy in patients with myeloma and relapsed lymphoma. Disease relapse remains the major cause of treatment failure after autologous SCT. Improvements in supportive care and treatment of post-transplant complications, a greater availability of alternative donors and advances in tissue typing have simultaneously improved the number of patients eligible for allogeneic transplantation and transplant outcome. The realization that an immunologically mediated graft-versus-leukaemia effect makes a major contribution to the curative effect of an allograft has led to the development of reduced-intensity conditioning regimens, which have substantially reduced the morbidity and mortality of allografting. Advances in the identification of patients whose outcome with standard chemotherapy is likely to be poor coupled with an increased awareness of the impact of pre-transplant co-morbidities on patient outcome has aided patient selection. The major challenges in allogeneic SCT are now the design of strategies which can reduce the major causes of transplant toxicity-principally acute and chronic graft-versus-host disease- and disease relapse which now represents the major cause of treatment failure.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
There are no UCL People associated with this publication
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by